GNI Group Ltd. (TYO:2160)

Japan flag Japan · Delayed Price · Currency is JPY
2,482.00
-85.00 (-3.31%)
At close: Feb 6, 2026
-24.21%
Market Cap138.17B -11.8%
Revenue (ttm)25.78B +13.8%
Net Income-822.34M
EPS-16.12
Shares Out55.67M
PE Ration/a
Forward PE28.87
Dividendn/a
Ex-Dividend Daten/a
Volume1,205,600
Average Volume1,273,120
Open2,517.00
Previous Close2,567.00
Day's Range2,444.00 - 2,519.00
52-Week Range1,469.00 - 4,410.00
Beta1.31
RSI46.71
Earnings DateFeb 13, 2026

About GNI Group

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue-associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company is involved i... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Employees 867
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 2160
Full Company Profile

Financial Performance

In 2024, GNI Group's revenue was 23.61 billion, a decrease of -9.22% compared to the previous year's 26.01 billion. Earnings were 1.10 billion, a decrease of -86.43%.

Financial Statements